Summary
107.27 -0.05(-0.04%)05/16/2024
Natera Inc (NTRA)
Natera Inc (NTRA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.04 | 4.60 | 1.75 | 38.82 | 122.69 | 83.01 | 416.09 | 327.35 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 97.18 | |
| Open | 96.95 | |
| High | 98.17 | |
| Low | 95.40 | |
| Volume | 594,845 | |
| Change | -0.04 | |
| Change % | -0.04 | |
| Avg Volume (20 Days) | 796,265 | |
| Volume/Avg Volume (20 Days) Ratio | 0.75 | |
| 52 Week Range | 36.90 - 98.82 | |
| Price vs 52 Week High | -1.66% | |
| Price vs 52 Week Low | 163.36% | |
| Range | 0.24 | |
| Gap Up/Down | -0.81 | |
Fundamentals | ||
| Market Capitalization (Mln) | 13,118 | |
| EBIDTA | -358,575,008 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 117.38 | |
| Book Value | 6.4970 | |
| Earnings Per Share | -3.1100 | |
| EPS Estimate Current Quarter | -0.7300 | |
| EPS Estimate Next Quarter | -0.7500 | |
| EPS Estimate Current Year | -2.4400 | |
| EPS Estimate Next Year | -1.2300 | |
| Diluted EPS (TTM) | -3.1100 | |
| Revenues | ||
| Profit Marging | -0.3024 | |
| Operating Marging (TTM) | -0.2021 | |
| Return on asset (TTM) | -0.1714 | |
| Return on equity (TTM) | -0.5059 | |
| Revenue TTM | 1,208,556,032 | |
| Revenue per share TTM | 10.3070 | |
| Quarterly Revenue Growth (YOY) | 0.5210 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 363,966,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 14.9045 | |
| Revenue Enterprise Value | 10.1331 | |
| EBITDA Enterprise Value | -27.5765 | |
| Shares | ||
| Shares Outstanding | 122,242,000 | |
| Shares Float | 118,472,671 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.05 | |
| Insider (%) | 3.45 | |
| Institutions (%) | 95.77 | |
05/09 23:28 EST - seekingalpha.com
Natera, Inc. (NTRA) Q1 2024 Earnings Call Transcript
Natera, Inc. (NASDAQ:NTRA ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - President, Clinical Diagnostics Alex Aleshin - General Manager Oncology and Chief Medical Officer Conference Call Participants Dan Brennan - TD Cowen Tejas Savant - Morgan Stanley Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Catherine Schulte - Baird Matt Sykes - Goldman Sachs Operator Thank you for standing by. My name is Greg, and I will be your conference operator today.
Natera, Inc. (NTRA) Q1 2024 Earnings Call Transcript
Natera, Inc. (NASDAQ:NTRA ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - President, Clinical Diagnostics Alex Aleshin - General Manager Oncology and Chief Medical Officer Conference Call Participants Dan Brennan - TD Cowen Tejas Savant - Morgan Stanley Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Catherine Schulte - Baird Matt Sykes - Goldman Sachs Operator Thank you for standing by. My name is Greg, and I will be your conference operator today.
05/09 19:31 EST - zacks.com
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Natera (NTRA) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Natera (NTRA) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
05/09 16:05 EST - businesswire.com
Natera Reports First Quarter 2024 Financial Results
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024. Recent Strategic and Financial Highlights Achieved positive cash flow of approximately $3.0 million1 in the first quarter of 2024. Generated total revenues of $367.7 million in the first quarter of 2024, compared to $241.8 million in the first quarter of 2023, an increase of 52.1%. Product revenues gre.
Natera Reports First Quarter 2024 Financial Results
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024. Recent Strategic and Financial Highlights Achieved positive cash flow of approximately $3.0 million1 in the first quarter of 2024. Generated total revenues of $367.7 million in the first quarter of 2024, compared to $241.8 million in the first quarter of 2023, an increase of 52.1%. Product revenues gre.
05/03 08:00 EST - businesswire.com
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to detect recurrence early in patients with early-stage breast cancer. The full study can be found here. The study evaluated a total of 1,136 prospectively collected and banked plasma samples from 156 early-sta.
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to detect recurrence early in patients with early-stage breast cancer. The full study can be found here. The study evaluated a total of 1,136 prospectively collected and banked plasma samples from 156 early-sta.
05/01 16:05 EST - businesswire.com
Natera to Report its First Quarter 2024 Results on May 9
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2024, after the market close on May 9, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera's First Quarter 2024 Financial Results Date: Thursday, May 9, 2024 Time: 1:30 p.m. PT (4:30 p.m. ET) Live.
Natera to Report its First Quarter 2024 Results on May 9
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2024, after the market close on May 9, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera's First Quarter 2024 Financial Results Date: Thursday, May 9, 2024 Time: 1:30 p.m. PT (4:30 p.m. ET) Live.
05/01 07:00 EST - businesswire.com
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test. This comes at a critical time for the healthcare industry, helping physicians navigate patient care given nationwide shortages of Rho(D) immune globulin therapy (RhIg). Natera's test can be performed as early as nine weeks gestation and determines fetal RhD status from the blood of a pregnant patient, including.
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test. This comes at a critical time for the healthcare industry, helping physicians navigate patient care given nationwide shortages of Rho(D) immune globulin therapy (RhIg). Natera's test can be performed as early as nine weeks gestation and determines fetal RhD status from the blood of a pregnant patient, including.
04/22 08:00 EST - businesswire.com
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting Natera's technology in the scientific literature. Landmark cutting-edge science and clinical trial data based on Natera's suite of products have been published in top journals, such as Science, Nature, Nature Medicine, and New England Journal of.
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting Natera's technology in the scientific literature. Landmark cutting-edge science and clinical trial data based on Natera's suite of products have been published in top journals, such as Science, Nature, Nature Medicine, and New England Journal of.
04/11 08:00 EST - businesswire.com
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney donor-derived cfDNA (dd-cfDNA) test as a leading indicator of kidney transplant rejection. The published manuscript can be found here. The ProActive study is the largest prospective dd-cfDNA study in kidney transplant recipients, with roughly 5,000 patients enrolled a.
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney donor-derived cfDNA (dd-cfDNA) test as a leading indicator of kidney transplant rejection. The published manuscript can be found here. The ProActive study is the largest prospective dd-cfDNA study in kidney transplant recipients, with roughly 5,000 patients enrolled a.
04/08 08:00 EST - businesswire.com
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of two major studies, DTRT-2 and Trifecta-Heart, showcasing the ability of the Prospera Heart donor-derived cfDNA (dd-cfDNA) test to detect rejection in adult and pediatric heart transplant recipients. These are the second and third peer-reviewed publications evaluating Natera's technology for use in heart transplantation. “We are encouraged by the resul.
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of two major studies, DTRT-2 and Trifecta-Heart, showcasing the ability of the Prospera Heart donor-derived cfDNA (dd-cfDNA) test to detect rejection in adult and pediatric heart transplant recipients. These are the second and third peer-reviewed publications evaluating Natera's technology for use in heart transplantation. “We are encouraged by the resul.
04/05 07:00 EST - businesswire.com
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 study that was presented at the European Association of Urology (EAU) Congress 2024 in Paris, France. The analysis evaluates outcomes in muscle-invasive bladder cancer (MIBC) patients who tested serially negative with Signatera™, Natera's personalized and tumor-informed molecular residual disease (MRD) test. Sponsored by Genentech, a member of th.
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 study that was presented at the European Association of Urology (EAU) Congress 2024 in Paris, France. The analysis evaluates outcomes in muscle-invasive bladder cancer (MIBC) patients who tested serially negative with Signatera™, Natera's personalized and tumor-informed molecular residual disease (MRD) test. Sponsored by Genentech, a member of th.
03/22 15:27 EST - seekingalpha.com
Natera: Capitalizing On The Positive Momentum Of Personalized Medicine
The global market size for personalized medicines is estimated to reach $1,233.23 billion by 2033, with North America experiencing significant growth in the oncology sector. Natera Inc., a diagnostic company, focuses on women's health, oncology, and organ health, with major revenue drivers including non-invasive prenatal tests and personalized molecular residual disease tests. Natera reported a 43% year-on-year increase in revenue in Q4 2023, with a goal to achieve cash flow break even by Q3 2024 or sooner.
Natera: Capitalizing On The Positive Momentum Of Personalized Medicine
The global market size for personalized medicines is estimated to reach $1,233.23 billion by 2033, with North America experiencing significant growth in the oncology sector. Natera Inc., a diagnostic company, focuses on women's health, oncology, and organ health, with major revenue drivers including non-invasive prenatal tests and personalized molecular residual disease tests. Natera reported a 43% year-on-year increase in revenue in Q4 2023, with a goal to achieve cash flow break even by Q3 2024 or sooner.
03/18 07:00 EST - businesswire.com
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a collaboration with the Fédération Francophone de Cancérologie Digestive and CHU Dijon Bourgogne on the CIRCULATE-PRODIGE-70 study, a randomized, multicenter, prospective phase III clinical trial in France investigating molecular residual disease (MRD)-guided adjuvant treatment in stage II colorectal cancer (CRC) patients. The study's main objective is to determine the benefit.
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a collaboration with the Fédération Francophone de Cancérologie Digestive and CHU Dijon Bourgogne on the CIRCULATE-PRODIGE-70 study, a randomized, multicenter, prospective phase III clinical trial in France investigating molecular residual disease (MRD)-guided adjuvant treatment in stage II colorectal cancer (CRC) patients. The study's main objective is to determine the benefit.
03/14 08:00 EST - businesswire.com
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, commented today on the 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, which was recently published by the Kidney Disease Improving Global Outcomes (KDIGO) organization, a leading medical society in nephrology. The updated guideline includes consensus statements supporting the use of genetic testing to establish the cause of chronic kidney disease.
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, commented today on the 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, which was recently published by the Kidney Disease Improving Global Outcomes (KDIGO) organization, a leading medical society in nephrology. The updated guideline includes consensus statements supporting the use of genetic testing to establish the cause of chronic kidney disease.
03/12 08:00 EST - businesswire.com
Natera to Present New Data at the 2024 SGO Annual Meeting on Women's Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, and hereditary cancer test, Empower™, at the 2024 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer taking place March 16-18, 2024. A total of seven abstracts will be presented, including two oral presentations and five poster presentations. Th.
Natera to Present New Data at the 2024 SGO Annual Meeting on Women's Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, and hereditary cancer test, Empower™, at the 2024 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer taking place March 16-18, 2024. A total of seven abstracts will be presented, including two oral presentations and five poster presentations. Th.
03/11 13:23 EST - youtube.com
Final Trades: Natera, Disney, Chubb and ASML Holding
The Investment Committee share their top stocks to watch for he second half.
Final Trades: Natera, Disney, Chubb and ASML Holding
The Investment Committee share their top stocks to watch for he second half.
03/07 08:00 EST - businesswire.com
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has received commercial insurance coverage for its Prospera Heart and Prospera Kidney tests from one of the largest Blue Cross Blue Shield (BCBS) plans in the U.S. Prospera is a non-invasive blood test that analyzes donor-derived cfDNA (dd-cfDNA) to evaluate the risk of organ transplant rejection. The coverage policy includes serial testing with Prospera to asse.
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has received commercial insurance coverage for its Prospera Heart and Prospera Kidney tests from one of the largest Blue Cross Blue Shield (BCBS) plans in the U.S. Prospera is a non-invasive blood test that analyzes donor-derived cfDNA (dd-cfDNA) to evaluate the risk of organ transplant rejection. The coverage policy includes serial testing with Prospera to asse.
03/04 13:06 EST - zacks.com
What Makes Natera (NTRA) a Strong Momentum Stock: Buy Now?
Does Natera (NTRA) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes Natera (NTRA) a Strong Momentum Stock: Buy Now?
Does Natera (NTRA) have what it takes to be a top stock pick for momentum investors? Let's find out.
02/28 21:30 EST - seekingalpha.com
Natera, Inc. (NTRA) Q4 2023 Earnings Call Transcript
Natera, Inc. (NTRA) Q4 2023 Earnings Call Transcript
Natera, Inc. (NTRA) Q4 2023 Earnings Call Transcript
Natera, Inc. (NTRA) Q4 2023 Earnings Call Transcript
02/28 19:31 EST - zacks.com
Compared to Estimates, Natera (NTRA) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Compared to Estimates, Natera (NTRA) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
02/28 16:05 EST - businesswire.com
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported its financial results for the fourth quarter and year ended December 31, 2023. Recent Strategic and Financial Highlights Generated total revenues of $311.1 million in the fourth quarter of 2023, compared to $217.3 million in the fourth quarter of 2022, an increase of 43.2%. Product revenues grew 44.3% over the same period. Generated total revenues of $1,082.6 million in the full.
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported its financial results for the fourth quarter and year ended December 31, 2023. Recent Strategic and Financial Highlights Generated total revenues of $311.1 million in the fourth quarter of 2023, compared to $217.3 million in the fourth quarter of 2022, an increase of 43.2%. Product revenues grew 44.3% over the same period. Generated total revenues of $1,082.6 million in the full.